P739 RISK FACTORS AND TREATMENT OUTCOMES IN GENOTYPE 1 AND GENOTYPE 4 HEPATITIS C INFECTED PATIENTS FROM A REAL WORLD DATA ANALYSIS IN EUROPE

P738 NO CLINICALLY RELEVANT DRUG–DRUG INTERACTIONS BETWEEN FALDAPREVIR AND PEGYLATED INTERFERON a-2a PLUS RIBAVIRIN IN HCV-INFECTED PATIENTS: PHARMACOKINETIC ANALYSES FROM TWO PHASE II STUDIES M. Bourliere, M. Sulkowski, M.P. Manns, T. Asselah, P. Ferenci, S. Pol, T. Berg, J. Lalezari, A.-M. Quinson, Y. Datsenko, J. Scherer, C.-L. Yong, F. Huang. Hopital Saint Joseph, Marseille, France; Johns Hopkins University School of Medicine, Baltimore, MD, United States; Hannover Medical School, Hannover, Germany; Hopital Beaujon, APHP, University Paris-Diderot and INSERM CRB 3, Clichy, France; Medical University of Vienna, Vienna, Austria; Hopital Cochin, Paris, France; Universitatsklinikum Leipzig AoR, Leipzig, Germany; Quest Clinical Research and University of California-San Francisco, San Francisco, CA, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States; Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany E-mail: mbourliere@hopital-saint-joseph.fr